Ornello R, Tiseo C, Frattale I, et al. - Given the approval of erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg, researchers sought to examine whether the 140 mg dose may provide more benefit to the patients with prior preventive treatment failures than the 70 mg. A review of the results of three randomized controlled trials and their subgroup analyses and open-label extensions was performed. Outcomes suggest that preference could be given to erenumab 140 mg monthly over the 70 mg monthly dose in patients with EM or CM and prior preventive treatment failures.